Virtual reality exposure and response prevention in the treatment of obsessive-compulsive disorder in patients with contamination subtype in comparison with in vivo exposure therapy: a randomized clinical controlled trial

被引:7
|
作者
Javaherirenani, Razieh [1 ]
Mortazavi, Seyede Salehe [2 ]
Shalbafan, Mohammadreza [3 ,4 ]
Ashouri, Ahmad [5 ]
Farani, Abbas Ramezani [5 ]
机构
[1] Iran Univ Med Sci, Tehran Inst Psychiat, Sch Behav Sci & Mental Hlth, Dept Clin Psychol, Tehran, Iran
[2] Iran Univ Med Sci, Tehran Inst Psychiat,Geriatr Mental Hlth Res Ctr, Sch Behav Sci & Mental Hlth, Tehran, Iran
[3] Iran Univ Med Sci, Psychosocial Hlth Res Inst, Sch Med,Dept Psychiat, Mental Hlth Res Ctr, Tehran, Iran
[4] Inst Cognit Sci Studies, Brain & Cognit Clin, Tehran, Iran
[5] Iran Univ Med Sci, Tehran Inst Psychiat, Sch Behav Sci & Mental Hlth, Dept Clin Psychol, Tehran, Iran
关键词
Contamination; Exposure and response prevention; Obsessive-compulsive disorder; Virtual reality; COGNITIVE-BEHAVIORAL THERAPY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; SYMPTOMS; METAANALYSIS; EFFICACY;
D O I
10.1186/s12888-022-04402-3
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Obsessive-Compulsive Disorder (OCD) is characterized by disturbing and unwanted thoughts as well as repetitive and time-consuming behaviors that interfere with performance. Cognitive Behavior Therapy (CBT) has shown to have beneficial effects on reducing OCD symptoms as the first line of treatment. Moreover, Virtual Reality (VR) has been a more feasible and accessible intervention for OCD in recent years. Regarding the point, the objective of this study was to evaluate the effectiveness of virtual reality exposure and response prevention (VRERP) in the treatment of the OCD contamination subtype. Methods: A total number of 36 adults with OCD-contamination subtype were registered and randomly assigned to the intervention and control groups. The intervention group received a 60-min CBT including a "contaminated"virtual environment while the control group received CBT as a standardized treatment. Out of these, 29 patients completed the treatment in 12 weekly sessions. The patients completed the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), Beck Depression Inventory-II (BDI-II), Beck Anxiety Inventory (BAI), Obsessive Beliefs Questionnaire-44(OBQ-44), and World Health Organization Disability Assessment Scale-2 (WHODAS-2) at week 0, week 12 and after 3 months follow-up. Results: Based on the results of the repeated measure analysis of variances, the total score of obsession and compulsion subscales of Y-BOCS significantly decreased as a primary outcome in the intervention group (F = 60.97, P < 0.001, partial eta squared = 0.82; F = 20.46, P < 0.001, partial eta squared = 0.61; F = 29.57, P <0.001, partial eta squared = 0.69; respectively). The total score of BDI-II and BAI was reduced in both groups but there was no significant difference between them (BDI-II: F = 0.54, P = 0.47, partial eta squared = 0.02; BAI: F = 3.12, P = 0.06, partial eta squared =0.19). However, there was a significant difference in the OBQ-44 (F = 16.78, P < 0.001, partial eta squared =0.56) and the total WHODAS-2 score between the groups (F = 14.64, P < 0.001, partial eta squared = 0.53). Conclusions: This study demonstrated the effectiveness of VRERP in the treatment of the OCD-contamination subtype. Therefore, VRERP can be used in CBT as an alternative exposure tool.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Virtual reality exposure and response prevention in the treatment of obsessive-compulsive disorder in patients with contamination subtype in comparison with in vivo exposure therapy: a randomized clinical controlled trial
    Razieh Javaherirenani
    Seyede Salehe Mortazavi
    Mohammadreza Shalbafan
    Ahmad Ashouri
    Abbas Ramezani Farani
    BMC Psychiatry, 22
  • [2] The effectiveness of metacognitive therapy in comparison to exposure and response prevention for obsessive-compulsive disorder: A randomized controlled trial
    Melchior, Kim
    van der Heiden, Colin
    Deen, Mathijs
    Mayer, Birgit
    Franken, Ingmar H. A.
    JOURNAL OF OBSESSIVE-COMPULSIVE AND RELATED DISORDERS, 2023, 36
  • [3] Metacognitive therapy versus exposure and response prevention for obsessive-compulsive disorder: study protocol for a randomized controlled trial
    Melchior, Kim
    Franken, Ingmar
    Deen, Mathijs
    van der Heiden, Colin
    TRIALS, 2019, 20 (1)
  • [4] Adding acceptance and commitment therapy to exposure and response prevention for obsessive-compulsive disorder: A randomized controlled trial
    Twohig, Michael P.
    Abramowitz, Jonathan S.
    Smith, Brooke M.
    Fabricant, Laura E.
    Jacoby, Ryan J.
    Morrison, Kate L.
    Bluett, Ellen J.
    Reuman, Lillian
    Blakey, Shannon M.
    Ledermann, Thomas
    BEHAVIOUR RESEARCH AND THERAPY, 2018, 108 : 1 - 9
  • [5] Metacognitive therapy versus exposure and response prevention for obsessive-compulsive disorder-A pilot randomized trial
    Glombiewski, Julia Anna
    Hansmeier, Jana
    Haberkamp, Anke
    Rief, Winfried
    Exner, Cornelia
    JOURNAL OF OBSESSIVE-COMPULSIVE AND RELATED DISORDERS, 2021, 30
  • [6] Efficacy of exposure and response prevention therapy in mixed reality for patients with obsessive-compulsive disorder: study protocol for a randomized controlled trial
    Lohse, Luzie
    Jelinek, Lena
    Moritz, Steffen
    Bloemer, Jannik
    Buecker, Lara
    Miegel, Franziska
    BMC PSYCHOLOGY, 2023, 11 (01)
  • [7] Exposure and Response Prevention for Postpartum Obsessive-Compulsive Disorder
    Gershkovich, Marina
    JOURNAL OF COGNITIVE PSYCHOTHERAPY, 2019, 33 (03) : 174 - 184
  • [8] Metacognitive therapy versus exposure and response prevention for obsessive-compulsive disorder - A non-inferiority randomized controlled trial
    Exner, Cornelia
    Kleiman, Alexandra
    Haberkamp, Anke
    Hansmeier, Jana
    Milde, Christopher
    Glombiewski, Julia Anna
    JOURNAL OF ANXIETY DISORDERS, 2024, 104
  • [9] A Preliminary Examination of Acceptance and Commitment Therapy Versus Exposure and Response Prevention for Patients with Obsessive-Compulsive Disorder on an Optimal Dose of SSRIs: A Randomized Controlled Trial in Iran
    Zemestani, Mehdi
    Salavati, Mojgan
    Seyedolshohadayi, Asrin
    Petersen, Julie M.
    Ong, Clarissa W.
    Twohig, Michael P.
    Ghaderi, Ebrahim
    BEHAVIOR MODIFICATION, 2022, 46 (03) : 553 - 580
  • [10] Metacognitive therapy versus exposure and response prevention for obsessive-compulsive disorder: study protocol for a randomized controlled trial
    Kim Melchior
    Ingmar Franken
    Mathijs Deen
    Colin van der Heiden
    Trials, 20